EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Model-Based Bioequivalence Analysis to Assess and Predict the Relative Bioavailability of Valproic Acid Formulations

Alejandra Schiavo, Pietro Fagiolino, Marta Vázquez, Iñaki Tróconiz, Manuel Ibarra

European Journal of Drug Metabolism and Pharmacokinetics · 2024

DOI: 10.1007/s13318-024-00901-8 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Drug Metabolism and Pharmacokinetics, 2024. Verfasst von Alejandra Schiavo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, Faculty of Chemistry, Universidad de la República, P.O. Box 1157, 11800, Montevideo, Uruguay. Hauptthemen laut MEDLINE: Valproic Acid, Therapeutic Equivalency, Biological Availability, Area Under Curve. Die Arbeit nennt 26 Literaturangaben. Gefördert von: Comisión Académica de Posgrado, Universidad de la República, Programa de Desarrollo de las Ciencias Básicas, Comisión Sectorial de Investigación Científica.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVE: Model-based bioequivalence (MBBE) encompasses the use of nonlinear mixed effect models supporting the estimation of pharmacokinetic endpoints to assess the relative bioavailability between multi-source drug products. This application emerges as a valuable alternative to the standard non-compartmental analysis (NCA) in bioequivalence (BE) studies in which dense sampling is not possible. In this work, we aimed to assess the application of MBBE compared to traditional methods in evaluating the relative bioavailability of two formulations with different drug release properties. Additionally, we sought to predict the performance of a modified-release formulation in a multiple-dose scenario, leveraging data from a single-dose study. METHODS: MBBE analysis was implemented to estimate the BE endpoints (90% CI for the Test/Reference geometric mean ratio, T/R GMR) in area under the concentration-time curve (AUC) and maximum concentration (Cmax) using data from a single-dose, 2-period, 2-sequence BE study performed in 14 healthy subjects between a locally developed valproic acid extended-release formulation (Test) and the brand-name delayed-release formulation (Reference). RESULTS: Results were compared with the standard approach, revealing that MBBE analysis achieved higher discrimination between formulations for Cmax, addressing limitations of the experimental sampling design and highlighting an advantage for this model-based analysis even when rich data are available. Additionally, the bioequivalence outcome under the multiple-dose scenario was predicted through a simulation-based study for both total and unbound valproic acid concentrations, considering the impact of valproic acid saturable binding on BE conclusions. CONCLUSIONS: The MBBE analysis was superior to the NCA approach in detecting product-related differences, overcoming limitations in the study experimental design. Predictions for the multiple-dose scenario preclude that the extended-release properties of the Test formulation would persist at steady state, resulting in lower peak-to-trough fluctuation and bioequivalent performance in terms of the extent of drug absorption. Overall, these results should discourage unnecessary experimentation in healthy subjects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Valproic AcidTherapeutic EquivalencyBiological AvailabilityArea Under CurveDelayed-Action PreparationsModels, BiologicalHumansMaleAdultYoung AdultAnticonvulsantsFemaleHealthy VolunteersCross-Over Studies

Substanzen

Valproic AcidDelayed-Action PreparationsAnticonvulsants

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, Faculty of Chemistry, Universidad de la República, P.O. Box 1157, 11800, Montevideo, Uruguay.
  • Graduate Program in Chemistry, Faculty of Chemistry, Universidad de la República, Montevideo, Uruguay.
  • Pharmacometrics and Systems Pharmacology Research Unit, Department of Pharmaceutical Sciences, School of Pharmacy and Nutrition, University of Navarra, Pamplona, Spain.
  • IdiSNA, Navarra Institute of Health Research, Pamplona, Spain.
  • Department of Pharmaceutical Sciences, Faculty of Chemistry, Universidad de la República, P.O. Box 1157, 11800, Montevideo, Uruguay. mibarra@fq.edu.uy.

Förderung

  • Comisión Académica de Posgrado, Universidad de la República
  • Programa de Desarrollo de las Ciencias Básicas
  • Comisión Sectorial de Investigación Científica

Zitieren

APA

Schiavo, A., Fagiolino, P., Vázquez, M., Tróconiz, I., & Ibarra, M. (2024). Model-Based Bioequivalence Analysis to Assess and Predict the Relative Bioavailability of Valproic Acid Formulations. European Journal of Drug Metabolism and Pharmacokinetics. https://doi.org/10.1007/s13318-024-00901-8

Vancouver

Schiavo A, Fagiolino P, Vázquez M, Tróconiz I, Ibarra M. Model-Based Bioequivalence Analysis to Assess and Predict the Relative Bioavailability of Valproic Acid Formulations. European Journal of Drug Metabolism and Pharmacokinetics. 2024. doi:10.1007/s13318-024-00901-8

BibTeX
@article{Schiavo2024,
  author = {Schiavo, Alejandra and Fagiolino, Pietro and Vázquez, Marta and Tróconiz, Iñaki and Ibarra, Manuel},
  title = {Model-Based Bioequivalence Analysis to Assess and Predict the Relative Bioavailability of Valproic Acid Formulations},
  journal = {European Journal of Drug Metabolism and Pharmacokinetics},
  year = {2024},
  doi = {10.1007/s13318-024-00901-8}
}
Kostenlos starten →